Generics

Innovative Products found!

Biosimilars

Medical devices

Nutraceuticals

Filters

Pp-069.2 manufacturers

Filters

Filters

Filters , active

Country of origin : Japan

Clear all

None products found

pp-069.2

Tablets

Dossier type
EU CTD
Dossier status
Under development
Country of origin
Japan
GMP approvals
EU GMP
Comments
Indication: Advanced or metastatic solid tumors with AKT pathway activation, including patients with germline PTEN mutations or tumors demonstrating PTEN loss or PI3K/AKT hyperactivation, particularly after exhaustion of standard therapy options. Clinical stage: Phase II development (global); ongoing precision-oncology studies focused on biomarker-selected populations. Modality: Small molecule (oral) Mechanism / Target: Selective AKT inhibitor that suppresses PI3K/AKT signaling, reducing tumor cell proliferation, survival, and metabolic activity in tumors dependent on this pathway. Route / form: Oral tablets Differentiation: Biomarker-driven, pathway-selective inhibition of AKT with potential for strong activity in PTEN-deficient and PI3K/AKT-activated tumors; offers a targeted approach where standard PI3K/AKT inhibitors show limited tolerability, aiming for a more manageable safety profile and improved precision targeting.
Manufacturer #38605

A research-driven pharma company developing therapies across oncology and other major diseases. It advances innovative medicines through global R&D and strategic alliances. The organization emphasizes high-quality manufacturing and patient impact.

 

 

Want to see all products?

Subscribe today to benefit from:

  • Streamlined product sourcing - the leading CTD dossiers database focused on finished dosage formulations

  • Direct negotiations - connect and negotiate directly with manufacturers without any brokerage fee

  • Increased profitability - secure the best commercial terms for your business by comparing offers from several manufacturers

Request Subscription

Interested in Subscription?

Please fill out form and send us your specific requirements, and we will get back to you as soon as possible

Want unlimited access to the Pipelinepharma database?

Become a subscriber to unlock:

  • Streamlined product sourcing: access the only CTD dossier pipeline and sourcing platform.

  • Direct connections: communicate directly with CTD dossier owners and manufacturers with no brokerage fees.

  • Higher profitability: compare multiple supplier offers and secure the best commercial terms.

  • Expanded network: view supplier portfolios and stay updated on new products.

  • Value-added product ideas: discover products with lower competition potential.

  • Access to marketing authorizations for sale: find already registered products in your target markets.